Tamtam Try Tamtam free
Kimball Electronics logo

Kimball Electronics account plan

Global contract electronics manufacturing

At a glance

Kimball Electronics is a Jasper, Indiana EMS and medical CDMO manufacturer with $1,431.4 million of FY2026 sales and about 5,600 employees.

Kimball Electronics (Nasdaq: KE), founded in 1961 and based in Jasper, Indiana, builds electronics and medical products to its customers' designs on a contract basis, combining electronics manufacturing services (EMS) with a contract development and manufacturing organization (CDMO) offer. It serves automotive, medical and industrial customers from plants in the United States, Mexico, Poland, Romania, China, Thailand and, since the July 1, 2026 Helvoet acquisition, the Netherlands and India. In fiscal 2026 (year to June 30, 2026) net sales were $1,431.4 million, down 4%, with operating income of $66.1 million and net income of $28.0 million. It employed about 5,600 people at June 30, 2026, about 1,000 of them in the US. Shareholders were asked at the November 13, 2026 annual meeting to rename the company Kimball Solutions, Inc. (ticker KMBL).

Business units

Strategic priorities

Build a global medical CDMO
The company aims to establish itself as "a true global medical CDMO platform", combining Helvoet in Europe and India with the new Indianapolis facility. Management expects medical to represent more than one-third of sales in FY2027.
Expand the package of value
Strategy is to move beyond PCBA work into complex system assembly, medical disposables, drug delivery, precision molded plastics and integrated CDMO, with emphasis on medical and pharmaceutical applications.
Leverage the global footprint
Plants in North America, Europe and Asia are positioned for customers seeking geographic diversification and supply-chain resilience; Helvoet adds the Netherlands and India.
Rebrand as Kimball Solutions
The Kimball Solutions brand, rolled out at sites from July 2026, covers the non-electronic portfolio; a company-wide name change to Kimball Solutions, Inc. was put to the November 13, 2026 annual meeting.
Grow sales at a 4.4% - 4.7% adjusted margin
FY2027 guidance is net sales of $1,535 - $1,560 million (high end expected), adjusted operating income of 4.4% - 4.7% of sales and capex of $50 - $60 million.

Latest results

In Q1 fiscal 2027 (three months to September 30, 2026) net sales rose 7% to $390.8 million from $365.6 million, with 3% organic growth and $12.4 million from Helvoet. Medical grew 14% (9% organic), Industrial 5% and Automotive 4%. Gross margin was flat at 7.9%, while operating income fell to $12.4 million (3.2% of sales) from $14.5 million and net income to $2.6 million ($0.11 per diluted share) from $10.1 million, hit by a 66.1% effective tax rate. Open orders rose 16% to $690 million and the customer count rose to 62. Management reiterated FY2027 guidance, with sales at the high end of $1,535 - $1,560 million.

Investments and deals

Helvoet acquisition
Bought on July 1, 2026 for about 90.0 million Euro ($103.0 million), the company's largest acquisition to date, funded with cash and credit lines; preliminary goodwill of $44 million and intangibles of $24 million.
Indianapolis medical CDMO facility
A new leased Indianapolis plant replaces the existing medical facility, with production expected to start in December 2026; the CFO put its FY2027 drag at about $6.5 - $7 million.
Capital expenditure
Capex was $51.7 million in FY2026, including the Indianapolis facility, and is guided at $50 - $60 million for FY2027.
Share repurchases
$118.6 million of the $140 million buyback authorisation had been used by September 30, 2026.
Divestments and closures
GES was sold to Averna Test Systems on July 31, 2024 for $18.5 million; the Tampa plant closed at June 30, 2025 and its site was sold on April 22, 2026 for $21.6 million.

Challenges and risks

Customer concentration
Nexteer Automotive (18%), Philips (11%) and ZF (11%) made about 40% of FY2026 net sales, and automotive customers face cyclical pressure.
Automotive demand
Automotive sales fell 7% in FY2026 on lower North American EV demand, and the 10-K expects "ongoing demand pressure in the automotive vertical" in FY2027.
Component supply and inflation
Memory and electronic components have tightened, with longer lead times and higher costs; costs passed through without margin dilute the operating margin.
High tax rate
The effective tax rate was 47.5% in FY2026 and 66.1% in Q1 FY2027 on dividend withholding taxes; the CFO called the expected low-30s rate too high.
Integration and ramp costs
Helvoet integration, partly debt-funded, and start-up costs at Indianapolis weigh on margins; borrowings rose to $235.7 million after the acquisition.

What leadership says

“We are expecting medical to continue to outpace the other two verticals and represent more than one-third of total company sales in the fiscal year”

Ric Phillips, Chief Executive Officer · Q4 and fiscal year 2026 earnings call, August 13, 2026

“Overall, I'm very pleased to see a return to growth and full year sales trending to the top end of our guidance range.”

Ric Phillips, Chief Executive Officer · Q1 fiscal 2027 earnings call, November 5, 2026

“our excitement for the overall strategic fit and growth opportunities of this new partnership are higher now than ever.”

Ric Phillips, Chief Executive Officer · On Helvoet, Q1 fiscal 2027 earnings call, November 5, 2026

“memory is affecting all of us and electronic components are also tight”

Jana Croom, Chief Financial Officer · Q1 fiscal 2027 earnings call, November 5, 2026

Where a supplier can help

Medical CDMO capacity ramp
The Indianapolis facility starting production and the Helvoet integration create needs for clean room, molding, sterilization, quality and validation suppliers tied to the medical CDMO priority.
Component sourcing and supply resilience
Tight memory and electronic component supply and rising inventory make sourcing, distribution and supply-chain visibility offers relevant to the component-supply challenge.
Cross-selling across the footprint
Helvoet's team was given AI-driven data-mining tools to find medical opportunities; sales intelligence and business development tools fit the top-line synergy priority.
Rebrand to Kimball Solutions
The company-wide rebrand creates work for branding, marketing, web and corporate-identity providers.
Margin and cost programmes
With an adjusted operating margin target of 4.4% - 4.7% and ramp costs at Indianapolis, automation and productivity offers can be tied to the margin priority.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Kimball Electronics?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Kimball Electronics

What does Kimball Electronics do?

It is a contract manufacturer offering electronics manufacturing services and medical CDMO solutions, building assemblies and devices for automotive, medical and industrial customers to their designs.

What is Kimball Electronics' revenue?

Net sales were $1,431.4 million in fiscal 2026 (year to June 30, 2026), down 4%. FY2027 guidance is $1,535 - $1,560 million, with the high end expected.

How many employees does Kimball Electronics have?

About 5,600 at June 30, 2026, about 1,000 of them in the US and 4,600 abroad.

Who leads Kimball Electronics?

Richard D. (Ric) Phillips has been CEO since March 2023; Jana T. Croom has been CFO since July 2021.

What is Kimball Electronics' strategy?

It aims to grow its medical CDMO business through the Helvoet acquisition and the new Indianapolis facility, expand into complex system assembly, drug delivery and molded plastics, and rebrand as Kimball Solutions.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)